These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. Orekhov AN; Bobryshev YV; Sobenin IA; Melnichenko AA; Chistiakov DA Int J Mol Sci; 2014 Jul; 15(7):12807-41. PubMed ID: 25050779 [TBL] [Abstract][Full Text] [Related]
9. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Kabakov AE; Tertov VV; Saenko VA; Poverenny AM; Orekhov AN Clin Immunol Immunopathol; 1992 Jun; 63(3):214-20. PubMed ID: 1623641 [TBL] [Abstract][Full Text] [Related]
10. [Antibodies against modified low-density lipoproteins and their complexes in blood of patients with various manifestations of atherosclerosis]. Belik IV; Ivantsova AA; Mamedova ZE; Denisenko AD Biomed Khim; 2016 May; 62(4):471-5. PubMed ID: 27563003 [TBL] [Abstract][Full Text] [Related]
11. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Tertov VV; Sobenin IA; Gabbasov ZA; Popov EG; Jaakkola O; Solakivi T; Nikkari T; Smirnov VN; Orekhov AN Lab Invest; 1992 Nov; 67(5):665-75. PubMed ID: 1434544 [TBL] [Abstract][Full Text] [Related]
12. [Cholesterol-containing circulating immune complexes--a component of the blood serum in patients with ischemic heart disease that determines its atherogenic properties]. Tertov VV; Kacharava AG; Saiadian KhS; Serebrennikov SG; Liakishev AA; Kozlov SG; Gratsianskiĭ NA; Rogova EM; Bocharova OI; Orekhov AN Kardiologiia; 1989 Aug; 29(8):35-8. PubMed ID: 2479794 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein immune complexes as markers of atherosclerosis. Orekhov AN; Kalenich OS; Tertov VV; Novikov ID Int J Tissue React; 1991; 13(5):233-6. PubMed ID: 1806545 [TBL] [Abstract][Full Text] [Related]
15. Occurrence of anti-low density lipoprotein antibodies and circulating immune complexes in aged subjects. Szondy E; Lengyel E; Mezey Z; Füst G; Gerö S Mech Ageing Dev; 1985 Feb; 29(2):117-23. PubMed ID: 3974305 [TBL] [Abstract][Full Text] [Related]
16. [An alternative hypothesis of the pathogenesis of atherosclerosis]. Bhakdi S Herz; 1998 May; 23(3):163-7. PubMed ID: 9646097 [TBL] [Abstract][Full Text] [Related]
17. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827 [TBL] [Abstract][Full Text] [Related]
18. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. Lopes-Virella MF; Virella G J Atheroscler Thromb; 2013; 20(10):743-54. PubMed ID: 23965492 [TBL] [Abstract][Full Text] [Related]
19. Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic disease. Andican G; Seven A; Uncu M; Cantaşdemir M; Numan F; Burçak G Scand J Clin Lab Invest; 2008; 68(6):473-8. PubMed ID: 18609113 [TBL] [Abstract][Full Text] [Related]
20. [Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk]. Yoshida H Rinsho Byori; 2010 Jun; 58(6):622-30. PubMed ID: 20662275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]